AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CFO Raffi Asadorian purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 13th. The stock was acquired at an average price of $3.13 per share, for a total transaction of $15,650.00. Following the purchase, the chief financial officer now owns 47,000 shares of the company’s stock, valued at approximately $147,110. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
NASDAQ ACRX traded down $0.10 on Tuesday, hitting $3.15. 154,061 shares of the stock traded hands, compared to its average volume of 6,058,886. AcelRx Pharmaceuticals Inc has a twelve month low of $1.65 and a twelve month high of $5.05. The stock has a market capitalization of $203.06 million, a P/E ratio of -2.87 and a beta of 2.03.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings data on Monday, November 5th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). The business had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $1.10 million. As a group, research analysts anticipate that AcelRx Pharmaceuticals Inc will post -0.86 EPS for the current fiscal year.
Several research analysts recently commented on the company. Zacks Investment Research upgraded AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of AcelRx Pharmaceuticals in a research note on Tuesday, November 6th. Cantor Fitzgerald boosted their price target on AcelRx Pharmaceuticals from $8.00 to $9.00 and gave the stock an “overweight” rating in a research note on Monday, November 5th. LADENBURG THALM/SH SH set a $10.00 price target on AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 2nd. Finally, ValuEngine upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, November 2nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $7.93.
TRADEMARK VIOLATION NOTICE: This article was posted by WKRB News and is the property of of WKRB News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/13/acelrx-pharmaceuticals-inc-acrx-cfo-raffi-asadorian-buys-5000-shares.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.